Hana Algül

18.5k citations
170 papers · 14.2k · 4 hit papers · h-index 46

Impact in

  • Oncology top 0.5%
    • Pancreatic and Hepatic Oncology Research
    • PARP inhibition in cancer therapy
    • Cancer Cells and Metastasis
    • Cancer Immunotherapy and Biomarkers
    • Cancer Genomics and Diagnostics

Papers in

    • Pancreatic and Hepatic Oncology Research 52
    • PARP inhibition in cancer therapy 8
    • Cancer Genomics and Diagnostics 15
    • NF-κB Signaling Pathways 9

Hana Algül

160 papers receiving 14.1k citations

Hana Algül's Hit Papers

Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer 2022 · 158 citations
1580+5+10Years since publication10002.0k3.0k4.0k

Peers

Hana Algül
Comparison fields: 5 of 160
  • Oncology 5.0k
  • Cancer Research 1.9k
  • Epidemiology 3.8k
  • Physiology 454
  • Immunology 1.9k
Replace Martín E. Fernández-Zapico with:
Martín E. Fernández-Zapico United States
Ken Shirabe Japan
Eric W. Jonasch United States
Umamaheswar Duvvuri United States
Sylvain Ladoire France
Sug Hyung Lee South Korea
Lixin Wei China
Phillip L. Lorenzi United States
Maria Tsokos United States
Fatima Mechta‐Grigoriou France
Hana Algül relative to Martín E. Fernández-Zapico United States Martín E. Fernández-Zapico's profile →
Citations per field
00.5×1.5×
Martín E. Fernández-Zapico · 1×
Citations per year

Countries citing papers authored by Hana Algül

Since Specialization
Citations

This map shows the geographic impact of Hana Algül's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hana Algül with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hana Algül more than expected).

Fields of papers citing papers by Hana Algül

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hana Algül. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hana Algül. The network helps show where Hana Algül may publish in the future.

Co-authors

The 25 scholars most cited alongside Hana Algül, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Hana Algül Line = papers co-authored together Hana Algül links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 170 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
Hit paper breakdown →
20164660
2
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Hit paper breakdown →
20191752
3
Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer
Hit paper breakdown →
2011731
4 2015469
5 2018312
6 2017284
7 2013239
8 2013236
9 2016234
10 2005174
11 2013165
12 2014161
13 2007158
14
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Hit paper breakdown →
2022158
15 2018149
16 2020149
17 2014144
18 2016134
19 2014119
20 2022115

About Hana Algül

Hana Algül is a scholar working on Oncology, Cancer Research, Surgery, Immunology and Pulmonary and Respiratory Medicine, having authored 170 papers that have together received 14.2k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (52 papers), Pancreatitis Pathology and Treatment (41 papers), Cancer Genomics and Diagnostics (15 papers), Gallbladder and Bile Duct Disorders (13 papers), Neuroendocrine Tumor Research Advances (9 papers), NF-κB Signaling Pathways (9 papers), PARP inhibition in cancer therapy (8 papers) and Phagocytosis and Immune Regulation (8 papers). The work is most often cited by research in Oncology (5.0k citations), Cancer Research (1.9k citations), Epidemiology (3.8k citations), Physiology (454 citations) and Immunology (1.9k citations). Hana Algül has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Marina Lesina, Roland Michael Schmid, Matthias Treiber, David Arthur Tuveson, Thomas Mathias Gress, Albrecht Neeße, Sonja M. Wörmann, Michele Reni, Anke Reinacher‐Schick and Do‐Youn Oh. Their work appears in journals such as Gastroenterology, Annals of Oncology, Pancreatology, Journal of Clinical Investigation and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact